References
Lafay-Cousin L, Bouffet E (2011) In response to “Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low grade glioma”. Support Care Cancer. doi: 10.1007/s00520-011-1309-3
Genc DB, Canpolat C, Berrak SG (2012) Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Support Care Cancer 20(2):385–393
Khaw SL, Coleman LT, Downie PA, Heath JA, Ashley DM (2007) Temozolomide in pediatric low-grade glioma. Pediatr Blood Cancer 49(6):808–811
Cappellano Am, Cavalheiro S, Bergamo M, Carmona P, Soares MFF, Tostes VS, Seixas MT, da Silva NS (2010) Vinorelbine in progressive unresectable low-grade glioma: experience of a single institution. Neuro-Oncology 12(6):ii20
Ater J, Holmes E, Zhou T, Mazewski C, Roberts W, Vezina G, Booth T, Freyer D, Kadota R, Jakacki R, Packer R, Prados M, Pollack I (2008) Results of the COG protocol 9952: a randomized phase 3 study of 2 chemotherapy regimens for incompletely resected low grade glioma in young children. Neuro-Oncology 10:452
Conflict of interest
The authors declare that they have neither a financial relationship with any organization nor with any sponsor. They also accept that the primary data which is under their control are allowed to be reviewed by the journal upon request.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Genc, D.B., Canpolat, C. & Berrak, S.G. Response letter to the editor. Support Care Cancer 20, 1119–1120 (2012). https://doi.org/10.1007/s00520-012-1421-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-012-1421-z